PRL-like protein A (PLP-A) is a member of the PRL family expressed in trophoblast cells coincident with establishment of the chorioallantoic placenta. The purpose of this investigation was to identify targets for PLP-A. Using an alkaline phosphatase-tagging strategy, we show that PLP-A specifically interacts with a population of natural killer (NK) lymphocytes within the mesometrial compartment of decidua from pregnant and pseudopregnant rats. These observations are supported by the codistribution of PLP-A targets with cells expressing the rat NK cell surface marker, gp42, the absence of PLP-A binding in conceptuses from NK cell-deficient tg⑀26 mice, and the specific interaction of PLP-A with a rat NK cell line, RNK-16. We have further demonstrated that PLP-A effectively suppresses RNK-16 cell cytolytic activities. Our results provide evidence for a new paradigm of embryonic-maternal communication involving a PLP-A signaling pathway between trophoblast cells and uterine NK lymphocytes. (Endocrinology 140: [2711][2712][2713][2714][2715][2716][2717][2718][2719][2720] 1999) 
T ROPHOBLAST cells are essential for modification of the maternal uterine environment into a hospitable site for embryonic and fetal development. This important task is accomplished at least in part via the elaboration of cytokines/hormones belonging to the PRL/GH family (1) . In the rat and mouse, this cytokine family contains at least 15 different members (1) . At this juncture, information is available on target cells and biological actions for only six members of the family, including those with luteotropic and lactogenic actions (1) and those regulating angiogenesis (2) . This includes PRL family members activating the PRL receptor [PRL and placental lactogen (PL) I, Iv, and II] (1) and those interacting with endothelial cells (proliferin and proliferinrelated protein) (2) . Targets and actions for the remaining members of the PRL family are presently unknown. Based on their homology, abundance, and cell-and temporal-specific patterns of expression during pregnancy, we hypothesize that each member of the uteroplacental PRL family participates in the paracrine/endocrine signaling required for ensuring viviparity.
We have implemented a strategy of tagging members of the uteroplacental PRL family with alkaline phosphatase (AP). These AP-cytokine fusion proteins have facilitated the identification of target tissues for members of the uteroplacental PRL family (3) . In the present report we begin to explore the biology of one member of the PRL family referred to as PRL-like protein A (PLP-A). PLP-A is expressed by trophoblast cells at the ontogeny of chorioallantoic placenta formation (4 -8) . PLP-A is considered a nonclassical PRL family member, in that it does not use the PRL receptor (1, 9) . At present, the target cells and actions of PLP-A are unknown.
Using the AP-tagging strategy, we show that PLP-A specifically interacts with a population of natural killer (NK) lymphocytes within the mesometrial compartment of uteri from pregnant rats and mice. NK cells participate in immune surveillance, where they effectively recognize and kill virally infected and transformed cells and secrete an array of bioeffector molecules (10 -12) . NK cells are conspicuous residents of the uterus of rodents and humans during pregnancy (11, (13) (14) (15) . The distribution and phenotype of uterine NK cells change from implantation to midgestation (11, 13) . At midgestation in the mouse and rat, the mesometrial decidual region is characterized by the presence of a prominent population of NK cells (11, 13, 16) . These uterine NK cells are juxtaposed to trophoblast cells of the developing chorioallantoic placenta and are distinct in their cytokine and bioeffector secretory profiles and their relative absence of cytolytic activities (17) (18) (19) (20) (21) . Our data indicate that PLP-A is a candidate regulator of the pregnancy-associated uterine NK cell phenotype. 
Materials and Methods Reagents

Animals and tissue preparation
Holtzman rats were obtained from Harlan Sprague Dawley, Inc. (Indianapolis, IN). A breeding colony of transgenic tg⑀26 mice (22) was maintained in the barrier-sustained environment of the isolation unit at the University of Guelph. Timed pregnancies and pseudopregnancies and tissue dissections were performed as previously described (23) (24) (25) (26) . The presence of a copulatory plug or sperm in the vaginal smear was designated day 0 of pregnancy. The first day of pseudopregnancy was defined as the first day of leukocytic vaginal smears after stimulation. Deciduomal responses were induced in pseudopregnant rats by the injection of 50 -100 l sesame oil/uterine horn on day 4 of pseudopregnancy (25) . Protocols for the care and use of animals were approved by the University of Kansas animal care and use committee.
Cell culture
Human fetal kidney 293 cells were used as hosts for the expression of AP fusion proteins. 293 cells were routinely maintained in MEM supplemented with 20 mm HEPES, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FBS. Some aspects of NK cell biology were evaluated in the rat NK cell line, RNK-16 (27, 28) . RNK-16 cells were maintained in RPMI 1640 culture medium supplemented with HEPES (10 mm), l-glutamine (2 mm), sodium pyruvate (1 mm), nonessential amino acids, 50 m 2-mercaptoethanol, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FBS. YAC-1 cells were used as targets for cytotoxicity assays and were maintained in RPMI 1640 culture medium supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FBS. CHO cells were used as hosts for the PRL receptor expression plasmid and were routinely maintained in DMEM/MCDB-302 culture medium containing 1 mm proline, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FBS.
Generation and characterization of the AP-PLP-A fusion protein
A fusion protein consisting of a modified human placental AP (PLAP) and rat PLP-A was generated and used to monitor PLP-A target cell interactions. Procedures for generating the fusion protein were similar to those previously reported for the generation of an AP-PL-I fusion protein (3) . A vector containing ampicillin and neomycin resistance genes and a secreted version of PLAP (SEAP) (29) situated downstream of a cytomegalovirus (CMV) promoter (pCMV/SEAP) was commercially obtained (Tropix). A nucleotide region representing the mature rat PLP-A protein was then amplified and ligated into the pCMV/SEAP vector. Ligation with the PLP-A insert resulted in a CMV promoterdriven vector containing the ligated cDNAs encoding a SEAP-PLP-A fusion protein (AP-PLP-A; see Fig. 1 ). DNA sequencing of the insert was performed to verify the accuracy of the PCR amplification. After linearization with BglII, the AP-PLP-A construct was electroporated into 293 human fetal kidney cells. After a 2-week selection with 500 g/ml G418, single clones were isolated by limiting dilution and were screened for AP expression. An unmodified pCMV-SEAP vector (AP) was similarly transfected, selected, and served as a negative control. Transfected 293 cells were cultured in MEM supplemented with 20 mm HEPES, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FBS in an atmosphere of 5% CO 2 -95% air at 37 C in a humidified incubator. After the cells reached confluence, the medium was changed to serum-free MEM and HEPES, further conditioned for 72 h, collected and clarified by centrifugation, sterile filtered (0.22 m), and stored at Ϫ20 C until used. AP activity was measured from conditioned medium via a colorimetric assay (3) . Western blot analysis for PLP-A was performed as previously described (9) . AP-PLP-A preparations were isolated from conditioned medium using immunoprecipitation with monoclonal antibodies to AP conjugated to agarose (Sigma Chemical Co.). Native PLP-A isolated from junctional zone conditioned medium and recombinant PLP-A isolated from 293 cells were used as controls for the Western blotting (8, 9) . PRL-like biological activities were assessed through the use of the rat Nb2 lymphoma cell proliferation assay (30, 31) and through incubation with CHO cells transiently transfected with the long form of the rat PRL receptor (32) .
Analysis of AP-PLP-A binding to tissues and cells
Tissues were frozen in heptane and stored at Ϫ70 C until tissue sections were prepared with the aid of a cryostat. Sections were mounted onto glass slides, washed in a modified HBSS (containing 20 mm HEPES, 0.5 mg/ml BSA, and 0.1% NaN 3 ), and incubated with AP, AP-PLP-A, or AP-PLP-A plus excess recombinant rat PLP-A, ovine PRL, or bovine GH for 75 min (5 g/ml each). Recombinant rat PLP-A was generated in 293 cells and purified as previously described (8, 9) . After incubation, the sections were washed with a modified HBSS supplemented with 0.1% Tween-20, heated at 65 C for 30 min to inactivate endogenous tissue AP activity, and processed for detection of the heat-stable AP activity associated with the fusion proteins, and coverslips were mounted in aqueous mounting medium. The specificity of binding was assessed by incubation with the AP control or addition of various peptide hormones. Cytospins of cultured RNK-16 cells (27, 28) , enzymatically dissociated uterine cells (see below), and transfected CHO cells directly adherent to culture plates were similarly processed. CHO cells were transiently transfected with an expression vector containing the long form of the rat PRL receptor (pECE/long) (32) using Lipofectamine according to the manufacturer's instructions. The AP-PL-I fusion protein (3) was used as a positive control for binding to the rat PRL receptor.
Identification of PLP-A in the midgestation rat conceptus
PLP-A messenger RNA was detected in frozen tissue sections from the rat day 9 conceptus using previously described procedures (33) . The full-length rat PLP-A cDNA (4) was linearized and used as a template for the synthesis of 35 S-labeled sense and antisense RNA probes. PLP-A protein was identified by immunocytochemistry in rat day 9 conceptus tissue sections as previously described (8) .
Immunocytochemical localization of gp42
The protein, gp42, is expressed on the surface of interleukin-2-activated rat NK cells and can be specifically recognized with the monoclonal antibody, 3G7-E (34, 35) . The gp42 protein was localized in frozen tissue sections of uteri from pregnant and pseudopregnant/decidualized rats using the 3G7-E monoclonal antibody and a streptavidin-biotin immunoperoxidase kit for mouse IgG (33, 34) . The specificity of the immunoreactions was demonstrated using nonimmune mouse IgG.
Immunomagnetic isolation of rat uterine NK cells
The 3G7-E monoclonal antibody to gp42 and magnetic cell sorting with antimouse IgG MicroBeads (Miltenyi Biotech, Auburn, CA) were used to isolate NK cells from uteri of pregnant and pseudopregnant/ decidualized rats. Decidual cells were dissociated from mesometrial decidua isolated on day 10 of gestation or from whole deciduoma isolated on day 10 of pseudopregnancy. Decidual tissue was minced with fine scissors and dispersed in Dispase (2.4 U/ml) containing deoxyribonuclease I (80 U/ml) for 1 h at 37 C. Dispersed cells were recovered by centrifugation and washed with HBSS to remove residual Dispase. Red blood cells were lysed via incubation of the cell suspensions with 10 vol lysis buffer (155 mm NH 4 Cl, 10 mm NaHCO 3 , and 0.1 mm EDTA) for 5 min at room temperature. Cells were recovered by centrifugation and washed twice in 10 vol PBS containing 2 mm EDTA and 0.5% BSA (isolation buffer). The cell preparation was adjusted to 10 7 cells/100 l and incubated with anti-gp42 (34) for 10 min at 5 C with continual mixing. Cells were then washed twice with 10 vol isolation buffer, recovered by centrifugation, resuspended at a final concentration of 10 7 cells/100 l, and incubated with antimouse IgG MicroBeads (Miltenyi Biotech) for 15 min at 5 C. After incubation, the cells were washed, resuspended in a final volume of 500 l isolation buffer, and loaded onto a Magnetic Separation Plus column (Miltenyi Biotech) affixed to a magnet. The column was washed three times with isolation buffer (500 l each), and the eluting cells were collected (gp42-immunonegative fraction). The column was then removed from the magnet, and cells were eluted in 1 ml isolation buffer (gp42-immunopositive fraction). Aliquots of cells from both fractions were adhered to glass slides and processed for PLP-A binding.
Cytotoxicity assays
NK cell cytolytic activities were monitored by 51 Cr release assay (36). YAC-1 target cells were incubated for 1 h at 37 C with 200 Ci 51 Cr. Radiolabeled YAC-1 target cells were washed three times and then incubated with RNK-16 cells to evaluate killing activity. The two populations of cells were coincubated at various ratios at 37 C, and after 4 h the amount of 51 Cr released into the culture medium was measured with a ␥-counter. Cells were exposed to medium conditioned by 293 cells mock transfected or transfected with a PLP-A expression vector, or they were exposed to an enriched preparation of recombinant PLP-A (purity, Ͼ90% by PAGE). Target cells in medium alone served as spontaneous release controls, and target cells in Triton X-100 served as maximal release controls. Spontaneous release values were subtracted from the test and maximal release values to calculate specific release. Data are presented as the mean Ϯ sem percentage of maximal killing.
Statistical analysis
Data were analyzed by ANOVA. The source of variation from significant F ratios was determined with Student's two-tailed t test (37) .
Results
Generation and characterization of the AP-PLP-A fusion protein
As a first step toward evaluating the biology of PLP-A, we generated and characterized an AP-PLP-A fusion protein.
The construction of the AP-PLP-A vector was achieved by in-frame insertion of the cDNA sequence of mature rat PLP-A downstream of the SEAP-coding sequence within the pCMV-SEAP vector (Fig. 1A) . The AP-PLP-A construct and an unmodified AP control vector were transfected via electroporation into 293 cells. The presence of AP activity was evaluated in conditioned medium from transfected cells and nontransfected cells using a colorimetric assay. Anti-PLP-A antibodies specifically recognized the AP-PLP-A fusion protein. AP and the AP-PLP-A fusion protein were initially enriched by immunoprecipitation with a monoclonal antibody to human PLAP conjugated to agarose. PLP-A antibodies recognized an AP-PLP-A protein species approximating 110 kDa and native PLP-A protein species of 29 and 33 kDa (Fig. 1B) . The 110-kDa M r of the AP-PLP-A fusion protein was consistent with the predicted M r of its AP and PLP-A components. The AP control preparation was not recognized by the PLP-A antibodies.
The AP-PLP-A fusion protein was also evaluated for its ability to activate the PRL receptor signaling system. Both AP-PLP-A and AP failed to stimulate the proliferation of rat Nb2 lymphoma cells (data not shown) and failed to bind to CHO cells transiently transfected with the long form of the rat PRL receptor (data not shown). In contrast, AP-PL-I controls effectively stimulated rat Nb2 lymphoma cell proliferation and interacted with the PRL receptor (data not shown).
These observations are consistent with earlier reports that PLP-A does not activate the PRL receptor signaling pathway (9) .
Identification of PLP-A targets with the AP-PLP-A fusion protein
We next examined the binding of AP-PLP-A to uteroplacental tissues during various stages of gestation. AP-PLP-A specifically bound to a population of cells situated in the midgestation mesometrial compartment of the deciduum immediately overlying the developing chorioallantoic placenta (Fig. 2, A-C) . This distinct binding pattern was first observed on day 9 of gestation in the rat, earlier than reported for PLP-A expression (4 -6). Consequently, we examined the expression of PLP-A messenger RNA by the rat day 9 conceptus and observed strong hybridization in developing trophoblast (Fig. 2, D and E rable tissue sections with AP failed to produce evidence of binding ( Fig. 2A) , and the binding of AP-PLP-A was specifically competed by the addition of PLP-A (Fig. 2C) , but not by coincubation with ovine PRL or bovine GH (data not shown).
The distribution of PLP-A binding in the midgestation rat conceptus was reminiscent of the distribution of NK cells in rat and mouse mesometrial decidua (Fig. 2F) (13, 14, 16, 38) . To clarify this relationship, we compared PLP-A binding with the localization of rat NK cells using a monoclonal antibody to gp42, a protein expressed on the surface of activated rat NK cells (34, 35) . gp42 has been previously shown to be expressed on differentiated rat uterine NK cells (13) . Similar distributions of PLP-A binding and gp42 immunoreactivity were observed in decidual tissues from days 9 -11 of pseudopregnancy or pregnancy and in the metrial gland from day 14 of pregnancy (Fig. 3) . The number of gp42-positive cells always outnumbered the number of AP-PLP-A-binding cells, especially on days 9 -11 of pregnancy or pseudopregnancy. Of particular interest was the association of gp42-positive cells and PLP-A-binding cells with the vasculature of the mesometrium and the developing metrial gland (Fig. 3) . In specimens from pregnant females, uterine NK cells radiated dramatically from developing trophoblast cells and were prominently associated with mesometrial vasculature, whereas NK cells developing in the absence of trophoblast were more randomly dispersed throughout the mesometrial compartment.
To further investigate the relationship between NK cells and PLP-A target cells, we used a monoclonal antibody to gp42 and an immunomagnetic cell separation strategy to isolate NK cells from decidual tissues of pregnant and pseudopregnant rats. The monoclonal antibody to gp42 facilitated the enrichment of PLP-A-binding cells (Fig. 4) . Pseudopregnant/decidualized uteri proved to be a richer source of gp42-positive cells than mesometrial decidua from conceptuses.
Additional evidence for uterine NK cells as targets for PLP-A was generated from binding experiments with midgestation conceptuses (day 10) from NK cell-deficient tg⑀26 mice (22) and a rat NK cell line, RNK-16 (27, 28) . AP-PLP-A specifically bound to cells in the mesometrial compartment of controls, but not in the NK cell-deficient conceptuses (Fig. 5) . Finally, AP-PLP-A specifically bound to cells of the rat NK cell line, RNK-16 (Fig. 5) . The extent of binding to RNK-16 cells was variable and may relate to their differentiation state. In summary, the data suggest that PLP-A specifically binds to a population of NK cells located in the mesometrial compartment of the decidua. 
Effects of PLP-A on NK cell cytotoxicity
NK cells are components of natural/innate immunity and participate in immune surveillance through their targeting of virus-infected cells, tumor cells, and potentially other cells for destruction without prior sensitization (10 -12) . The phenotype of uterine NK cells during pregnancy is characterized by their reduced capacity for killing (11, (17) (18) (19) 39) . Thus, we examined the effects of PLP-A on killing activity of RNK-16 cells toward YAC-1 cells. PLP-A significantly inhibited RNK-16 cell killing in a dose-dependent manner (Fig. 6 ) without directly affecting the viability or proliferation of either RNK-16 or YAC-1 cells. The data are consistent with the participation of PLP-A in the regulation of the pregnancyspecific uterine NK cell phenotype.
Discussion
The uteroplacental PRL family is emerging as a family of hormones/cytokines pivotal to the establishment of pregnancy (1, 2, 40) . In this report we have shown that the trophoblast-specific cytokine, PLP-A, specifically interacts with a population of cells situated in the mesometrial decidual compartment of both pregnant and pseudopregnant uteri. The distribution of cells binding PLP-A mirrors the intrauterine distribution of NK cells. In fact, PLP-A specifically binds to NK cells isolated from the uterus and from a rat NK cell line.
Uterine NK cells have been proposed to participate in immunological adjustments to pregnancy and in the establishment of the chorioallantoic placenta (13, 14, 38) . During pregnancy, NK cells undergo considerable morphological and functional changes, creating, in effect, a NK cell with a unique phenotype. Midgestation uterine NK cells are distinct in their cytokine and bioeffector secretory profile and their relative absence of cytolytic activities (17) (18) (19) (20) (21) . Further evidence from genetically mutant mice possessing defective cytolytic activities clearly indicate that NK cell cytolytic activities are not required for a successful pregnancy (41, 42) .
However, there is some evidence suggesting that aberrant uterine NK cell cytolytic activity is associated with pregnancy termination (43) (44) (45) (46) (47) . Presumably, dysregulated maternal uterine NK cells target genetically foreign extraembryonic and embryonic cells for destruction. Specific cause and effect relationships between uterine NK cells and pregnancy termination have not been established. Although NK cell cytolytic activities are not required for normal progression of pregnancy, it is apparent from studies on NK celldeficient mice that noncytolytic actions of NK cells are essential for normal uterine vasculature and chorioallantoic placental development (48 -50) . Thus, it is evident that uterine NK cell transformation into a pregnancy-dependent phenotype is vital for normal progression of the gestational state. Some of the maturational changes accompanying the pregnancy-dependent uterine NK cell phenotype occur in the absence of extraembryonic and embryonic tissues (51) (52) (53) , whereas other changes are probably dependent upon modulators produced by extraembryonic sources. The nature of the modulators controlling the pregnancy-dependent uterine NK cell phenotype is yet to be resolved.
Several years ago, Parr and co-workers postulated the idea of PRL or PRL-related proteins arising from decidual or placental tissues as regulators of uterine NK cells (54) . They proposed that uteroplacental PRL family members participated in transforming uterine NK cells into their pregnancyspecific phenotype. Indeed, ligands for the PRL receptor are secreted throughout gestation via either decidual (decidual luteotrophin) or trophoblast (PL-I, PL-II, and PL-I variant) tissues (1, 55) . Furthermore, PRL is known to interact with and influence an array of different immune cells, including NK cells (56, 57) . The surfaces of NK cells possess PRL receptors (58) , and PRL appears to synergize with interleukin-2 to promote NK cell activation, including killing activities (59) . Such actions are not entirely consistent with the midgestation uterine NK cell phenotype, which exhibits limited cytolytic activities (17) (18) (19) . Another PRL family member in -FIG. 6 . PLP-A modulation of RNK-16 cell cytolytic activities. Effects of PLP-A on RNK-16 cell cytolytic activity against YAC-1 cells. Cells were exposed to medium conditioned by 293 cells (mock transfected or transfected with a PLP-A expression vector), or they were exposed to an enriched preparation of recombinant PLP-A (ϳ1 g/ml; purity, Ͼ90% by PAGE). Note that control cells killed to a level of 36%, whereas NK cells exposed to PLP-A showed diminished killing. NK cells exposed to 100% 293-PLP-A conditioned medium (293-PLP-A CM) significantly decreased killing (P Ͻ 0.05), whereas exposure to the recombinant PLP-A preparation diminished killing even more (P Ͻ 0.01). PLP-A did not significantly affect the viability or proliferation rates of RNK-16 or YAC-1 cells (data not shown). CM, Conditioned medium.
vestigated in the present report, PLP-A, is a new candidate regulator of uterine NK cell function during pregnancy. PLP-A specifically binds to uterine and some nonuterine NK cells and can inhibit the cytolytic activities of rat NK cells (present study). PLP-A binding appears to be best associated with NK cell activation, as demonstrated by rat uterine NK cells expressing the activation surface protein, gp42. In further support of a regulatory role for PLP-A during pregnancy, trophoblast cell expression of PLP-A coincides with the appearance of proximally located NK cells with diminished cytolytic activities (Refs. 4 -8 and 19 and the present study). Whether PLP-A participates in the modulation of uterine NK cell killing or other aspects of the pregnancydependent uterine NK cell phenotype remains to be determined.
The nature of PLP-A's actions on NK cells is not known. PLP-A does not interact with the PRL receptor (Ref. 9 and the present study). Consequently, PLP-A actions are probably mediated by alternative signaling pathways. It is not entirely clear whether specific and unique receptor signaling systems have coevolved with each PRL family member, whether PRL family members use signaling pathways for other known ligands, or whether PRL family members act through receptor-independent mechanisms (e.g. transport proteins, binding proteins, etc.). PGs have been implicated in mediating pregnancy-associated changes in the uterine NK cell phenotype (47, 60, 61) and may represent an intracellular mediator of PLP-A action.
In summary, using the AP-tagging strategy, PLP-A is shown to specifically interact with a population of NK cells within the mesometrial compartment of the pregnant uterus. NK cells comprise part of the maternal immune surveillance with potent cytolytic activities and represent a rich source of bioeffector molecules. Appropriate modulation of uterine NK cells is critical for the establishment of vascular connectivity between mother and embryo without immunological rejection of the embryo. We propose that PLP-A participates in the regulation of uterine NK cells during pregnancy. Our results provide evidence for a new paradigm of embryonicmaternal communication involving a PLP-A signaling pathway between trophoblast cells and uterine NK cells.
